BioVeris Licenses Vaccine Candidates For Six Organisms From Baxter
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the agreement, BioVeris will pay Baxter a license issue fee as well as milestone payments and royalties.
You may also be interested in...
Baxter Suspends PreFluCel Studies Until Phase II/III Data Are Analyzed
Due to a higher than expected rate of mild fever and associated symptoms in a European trial, Baxter places PreFluCel clinical trials planned for 2005 on hold. PreFluCel is based on Baxter's vero cell technology platform.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products